“At Synaffix, our core values include scientific excellence, transparency and embracing the collective genius across the entire team.” – Peter van de Sande, CEO
We are passionate about delivering cutting-edge enabling technologies and best-in-class targeted cancer therapeutics.
In joining Synaffix, you join a fast-paced, highly collaborative team where innovation is at the center of everything we do.
Our efforts are aimed at improving the health of patients globally and to realize our ambition – Connect to Cure™.
If you are interested in becoming part of our exciting and dynamic team, please get in touch with us at .
Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
toxSYN™ Linker-Payload
Mode-of-Action
Payload (Active Catabolite)
1. SYNtecan E™*
Topoisomerase 1 inhibitor
Camptothecin-based
2. SYNeamicin D™*
DNA damaging agent
Calicheamicin-based
3. SYNeamicin G™*
4. SYN-PNU™*
Nemorubicin-based
5. SYNstatin E™
Microtubule inhibitors
Auristatin-based
6. SYNstatin F™
7. SYNtansine™
Maytansine-based
* Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace™